Print | Email Page

Celgene defends its leading product Revlimid® against patent revocation actions in UK

August 2018

Jones Day acted for Celgene Corporation in multiple cases brought by Accord Healthcare in the UK High Court (patents court) in relation to Celgene's patents concerning its best-selling drug, Revlimid®. The Firm is also assisting Celgene with coordination respecting Revlimid® patent protection across Europe.

Accord Healthcare Limited v. Celgene Corporation, HP 2017 000036, 000038 (UK High Court)

For additional information about this matter, please contact: Anthony M. Insogna, Alastair J. McCulloch

Client(s): Celgene Corporation
Office(s): San Diego, London, Chicago